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Childhood obesity is a serious problem growing worldwide that needs 
to be early considered and treated. Maternal overweight and obesity 
lead to foetal complications and to an increased risk of child obesity. 
Blueberry bio-active compounds have antioxidant properties and 
improve insulin sensitivity in obese individuals. We proposed a daily 
integration of a freeze-dried blueberry extract in the last trimester of 
a population of overweight and obese pregnant women. Mother 
cytokine milieu, birth weight and at age one, were compared with a 
matched control group.   
Results: birth weight was significantly lower in those whose mothers 
assumed the blueberry extract (male: 3636 gr ± 56,7 in control group 
and 3302 gr ± 60,9 in the blueberry, P=.001; female: 3446 gr ± 53 in 
control group and 3094 gr ± 65,5 in the blueberry, P<.0001) and this 
result remained comparable at age one (male control group: 9597 gr ± 
134,4; blueberry: 8656 gr ± 271,9; P=.0021; female control group: 8812 
± 167,5; blueberry: 8083 ± 266,3; P=.0211); pro-inflammatory 
cytokines (TNF-α and leptin) were significantly reduced in the 
blueberry group (control 29,89 pg/mL ± 0,283 vs blueberry 8,124 
ng/mL ± 0,1085 and 17,28 ± 0,4742 vs 6,977 ± 0,1187, respectively); 
anti-inflammatory cytokines (TGF-β and IL-4) were significantly 
increased in the blueberry group (control 4,196 pg/ml ± 0,9752 vs 
blueberry 14,87 pg/ml ± 0,8844 and 14,87 pg/ml ± 0,8844  vs 55,22 ± 
1,47, respectively), CRP levels were significantly lower in the blueberry 
group (control 5,917 mg/L ± 0,698 vs blueberry 3,741 mg/L ± 0,6279).   
Conclusion: a daily dietary supplementation with bioactive from whole 
blueberries in overweight and/or obese pregnant women is an 
effective intervention to reduce the risk of foetal macrosomia and 
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1. Introduction  
  
a. Epidemiology   
  
Childhood overweight and obesity are global burden diseases. 
The prevalence of this disorders increased from 4,2% in 1963-65 to  
15,3% in 1990-2000 and have plateaued during the first decade of the 
21st century1.   
The Italian registry of overweight and obesity showed that in 
year 2016 21,3% of children were overweight and 9,3% were obese 
with higher incidence in the southern part of the country (see Figure 1 
and 2)2.   
 
Figure 1: Italian childhood overweight and obesity trend in the last 8 years. Note that overweight interests ca. 
21,3% of the paediatric population and obesity ca. 9,3%. Fortunately the trend is favourable and the 
prevalence is slightly decreasing.  
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 BMI < 25 kg/m
2   25 kg/m
2 ≤ BMI ≤ 35 kg/m2    BMI > 35 kg/m
2  
  
Figure 2: Higher BMIs are present in the central and southern part of the country.  
  
The Swiss registry for overweight in 2017 registered a prevalence 
of 20% of overweight children and 7% of obese children3.   
  
b. Definition of childhood obesity  
  
There are internationally agreed threshold of body-mass index 
(BMI) for defining under-weight, normal-weight, overweight and 
obesity in adults, but in children, the marked effects of age, gender, 
pubertal status and race/ethnicity on growth make classification 
difficult. Commonly used cut points for childhood overweight and 
obesity include: 110% or 120% of ideal weight for height; weight-
forheight Z-scores of >1 and >2, and BMI at the 85th, 90th, 95th and 97th 
percentiles (based on international or country-specific reference 
populations, see Table 1).   
Age  0-2 years  2-5 years  5-18 years  
Marker  Weight for height  BMI  BMI  
Reference  OMS 2006  OMS 2006  OMS 2007  
> 85th Percentile  Overweight risk  Overweight risk  Overweight  
> 97th Percentile  Overweight  Overweight  Obesity  
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> 99th Percentile  Obesity  Obesity  Severe obesity  
  
Table 1: Diagnostic criteria for childhood overweight and obesity.  
  
c. Determinants and risk factors for childhood obesity  
  
Overweight is a complex condition which is influenced by a wide-
range of genetic and non-genetic factors, with interactions between 
many of these. Figure 3 shows a simplified model of the leptin 
signalling pathway, the key biological pathway that controls energy 
balance.   
  
  
Figure 3: Both insulin and leptin are secreted in proportion to body fatness and serve as adiposity signals, 
acting on the same neurons of the hypothalamic arcuate nucleus to regulate energy homeostasis. Ghrelin, 
which is secreted by the stomach and duodenum, serves as a hunger signal at the hypothalamus and 
brainstem, while other peptides secreted by the GI tract, including PYY, act as satiation signals. The ligands 
leptin, POMC, CART and BDNF, the receptors for leptin, melanocortins, and BDNF, and the enzyme PC1 have 
been found to have function-altering mutations associated with obesity in children. Mutations in the ligands 
and receptors for NPY, AGRP, CPE and MCH have been found to alter energy balance in rodents, but have not 
been as convincingly shown to be associated with human obesity. Lines with arrowheads indicate stimulatory 
action. Lines ending with a perpendicular end-block indicate inhibitory action.   
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d. Complications associated with childhood obesity  
  
Obesity can adversely affect nearly every organ system (see 
Figure 4) and often cause serious consequences, including 
hypertension, dyslipidaemia, insulin-resistance/diabetes, fatty liver 
disease and psychosocial complications4.  
 
Figure 4: Image obtained by dual energy X-ray absorptiometry from a teenage girl with BMI 38 kg/m2. 
Conditions that are of high prevalence and are well-established in their association with childhood obesity are 
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Weight gain result in lipid accumulation and adipocyte stress, 
factors known to disrupt the balance of systemic cell signalling 
(adipokines and cytokines).   
Macrophage accumulation in proportion to adipocyte size may 
increase the adipose tissue production of these proinflammatory and 
acute-phase molecules; since the cross talk between macrophages and 
adipocytes may negatively influence cellular insulin sensitivity5 this 
consequently aggravates the obesity state6,7 (see Figure 5).   
  
  
Figure 5. Adipose tissue macrophages in mice with varying degrees of adiposity. Adipose tissue macrophage 
accumulation is directly proportional to measures of adiposity in mice and humans. Adipose tissue produces 
several proinflammatory, procoagulant, and acute-phase molecules in direct proportion to adiposity. Among 
these molecules, TNF-a, IL-6, PAI-1, NO, factor VII, and MCP-1 have been implicated in the development of 
adverse pathophysiological phenotypes associated with obesity.   
  
  
e. Treatment and prevention strategies  
  
The current role-model of treatment of an obese children is 
multidisciplinary and focuses on a non-pharmacological; 
pharmacological and eventually surgical treatment8.   
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The Italian Swiss reality offers two specific multidisciplinary 
program for the care of children with adiposity; one is called OTTIMIX® 
(see Figure 6) (dedicated to groups of children aged < 8 years) and the 
second is called ADOFIX® (see Figure 7), an individual program directed 
to older children.   
Our multidisciplinary team is composed by a paediatrician (with 
a specific formation on childhood adiposity); a dietician; a 
psychologist; a physiotherapist; a ergo-therapist; an educator; a chef 
and an art-therapist. These programs integrate a larger Swiss program 
called “S3PIO” (Swiss Project for Precocious Prevention of Infantile 
Obesity).    
With the large number of personnel and intensity of 
interventions, these programs usually have high operating expenses 
and are exacerbated by low recruitment rates or high rates of 
attrition9. Therefore, prevention, especially in the young, is universally 
viewed as the best approach for reversing the rising global prevalence 
of obesity10.   
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Figure 6. Group program for overweight and obese children in the Italian Region of Switzerland; this program 
is dedicated to younger children (< 8 years) and it is active since 2012.  
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Figure 7. Individual program for overweight and obese children; this program is dedicated to older children (8-
16 years old) and it is active since 2016.   
  
f. The first 1000 days  
  
Particular opportunities for effective prevention of obesity and 
associated non-communicable diseases (NCDs) exist in pregnancy, in 
infancy and in early childhood; the first 1000 days, that describes the 
period from conception through age 2 years, is increasingly recognized 
as a critical period for development of childhood obesity and its 
adverse consequences11.   
Specifically, higher maternal pre-pregnancy BMI and excessive 
gestational weight gain have a consistent relationship with offspring 
overweight later in childhood and with adverse pregnancy outcomes12.   
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The antenatal period, with opportunities for regular contact 
with health professionals, is considered an ideal time to intervene 
because mothers are motivated to make changes that could optimise 
their outcome and that of the baby13.   
  
g. The “Developmental origins of health and disease (DOHaD)” 
paradigm   
  
The recent and rapid worldwide increase in NCDs, challenges the 
assumption that genetic factors are the primary contributors to such 
disease14.   
The “DOHaD” paradigm states that the environment during the 
preconception, gestation and lactation period shapes the developing 
individuals leading, in the case of a deleterious environment, to a 
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Figure 8: 1. The foetal origins of adult disease hypothesis. Adverse environmental cues from the mother are 
signalled to the developing foetus. The prevailing conditions may be sufficiently harsh to result in the loss of 
the pregnancy, or alternatively the foetus may mount adaptive responses to ensure immediate survival. One 
of these responses may be a slowing of growth that will ultimately result in lower weight at delivery. Other 
aspects of the adaptive response, which may be localized to specific organs and tissue types, will serve to 
modify physiology and metabolism, and hence tissue functions. The trade-off for overcoming the challenge in 
foetal life may be increased risk of disease in later life.  
  
This theory was popularised by D.J. Barker in the early 1990s15 and 
has recently become a famous topic (see Figure 9).  
  
  
Figure 9. “TIME” cover in 2010. The “DOHaD” paradigm cited by Barker received media consideration that 
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h. Epigenetics  
  
More and more studies are converging to propose that 
epigenetics may be one of the key molecular mechanisms underlying 
the developmental programming of the phenotype.   
Epigenetics refers to the field of science studying the heritable 
mechanism regulating gene expression without changing in the DNA 
sequence itself. There are two main physio-pathological mechanism 
that are illustrated and commented in Figure 9.   
 
Figure 10. Main mechanisms at the basis of epigenetics: covalent modification of the chromatin and noncoding 
RNA. The principal chromatin modifications are mostly in CpG dinucleotide configurations, and 
posttranslational modifications including methylation and acetylation of the histone proteins forming the 
nucleosome. These modifications are set-up or removed by the enzymes of the epigenetic machinery, leading 
to a dynamic state of the chromatin. The combination of all epigenetic marks over the genome constitutes the 
epigenome. The epigenetic landscapes are transmitted through cell division, leading to a memory of the cell 
identity, which leads to the notion of their ‘heritability’.  
  
Because of its  dynamic nature epigenetic can be sensitive to the 
environment. In fact it has been demonstrated a link between 
nutrition, energy metabolism and epigenetic processes16.   
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Green  leafy  vegetables  and  blueberries  have  been 
demonstrated to have important antioxidant properties thanks to 
polyphenols  and  phenolic  bioactive  compounds  such  as 
anthociyanines17.   
Both anthocyanins and proanthocyanins have been shown to 
reduce inflammation via the NF-kB and TNF-α pathways18,19. Other 
studies have established that blueberries attenuate bacterial 
translocation to extraintestinal sites, a phenomenon implicated in the 
inflammatory and metabolic pathology associated with diets high in 
fat20 and that they inhibit macrophage infiltration in adipose tissue, 
reduce their activation  and consequently reduce adipocyte death with 
the final result of improving significantly insulin sensitivity21,22.   
In addition phenolic extracts have been demonstrated to be 
capable to reduce production of nitric oxide and prostaglandin E-2, the 
expression of inducible nitric oxide synthase and cyclooxygenase in 
lipopolysaccharide-stimulated RAW 264.7 macrophage23.   
More recently it has been proved that blueberry anthocyanins 
are able to increase the total antioxidant capacity of the retina in 
diabetes subjects by reducing VEGF and IL-1β levels and by enhancing 
the activation of Nrf2/HO1 signalling, an important modulator of cell 
death and proliferation24.   
A reduction in inflammatory status by anti-inflammatory agents 
could constitute a potential approach to reduce adverse 
obesityassociated consequences.  
Low consumption of fruit and vegetables is common throughout 
the world25; because of its feasibility a dietary supplementation with 
bioactive components in blueberries is an attractive dietary 
intervention in order to increase and maintain an individual’s fruit and 
vegetables consumption over a long period of time26.   
    
  
2. Our approach and study design  
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Considering these dogmas and considering the elevated 
therapeutic frustration in achieving results with overweight and obese 
individuals, it was our goal to consider an efficacious alternative way 
to prevent childhood adiposity.   
The project’s overall objective was to examine the role of dietary 
supplementation with bioactive in freeze-dried whole blueberry 
powder on pro-inflammatory (TNF-α, IFN-γ, Leptin, C-reactive 
protein) and anti-inflammatory (IL-4 and TGF-β) adipokines and 
cytokines in nulliparous overweight or obese pregnant women and on 
birth weight and at age one.  
We hypothesized that increased daily consumption of blueberry 
bioactive, based on pre-clinical data, would be effective in reducing 
pro-inflammatory and in increasing anti-inflammatory adipokines and 
cytokines therefore reducing systemic inflammation and ultimately 
result in reducing new-born birth weight and at age one.   
The study design is a controlled clinical trial.    
  
    
3. Materials and Methods   
  
a. Study population  
  
This study is part of the ”S3PIO Program” (Swiss Project for 
Precocious Prevention of Infantile Obesity), a Swiss community base 
cohort in Canton Ticino.   
Approval for the study was obtained by Ethic Commission of the 
Ente Ospedaliero Cantonale (EOC). All woman provided written 
informed consent. Parents or caretaker provided written informed 
consent for the health check at one year of age.   
  
i. Phase 1  
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The Phase 1 of the study was conducted between January 2014 
and December 2014. All nulliparous pregnant woman (starting number 
= 900) with a BMI (calculated as weight (kg)/[height(m)]2) more than 
25 (overweight/obese and severely obese), starting from 13 weeks of 
gestation; (IQR, 12-14 weeks; n= 117; 13,3%) that underwent a first 
Gynaecological and Obstetrical visit were invited to participate in the 
study. 15 women denied their consent. 102 women agreed to 
complete the study and to enter in the Control group.   
  
ii. Phase 2  
  
The Phase 2 of the study was conducted between January 2016 
and December 2016. All nulliparous pregnant woman (starting number 
= 872) with a BMI (calculated as weight (kg)/[height(m)]2) more than 
25 (overweight/obese and severely obese), starting from 13 weeks of 
gestation; (IQR, 12-14 weeks; n= 107; 12,2%) that underwent a first 
Gynaecological and Obstetrical visit were invited to participate in the 
study. 2 women denied their consent. 105 women agreed to complete 
the study and to enter in the Blueberry group.   
All woman were asked to attend a periodic monthly diet and 
medical visit.   
Women who gave birth to twins, delivered preterm (< 37 weeks 
of gestation), with history of psychiatric disease prohibiting adherence 
to study protocol, history of allergic reactions to blueberries, 
consuming  berries, grapes and wine more than 3 times a week, with 
diabetes or consuming lipid-altering medication (e.g. thyroid 
hormones, steroids, sleep medications, insulin use and epileptic 
drugs), and actively smoking, were excluded.   
Birth outcomes (gestational age at birth, sex, birth weight and 
congenital abnormalities) were obtained; new-born with suspected or 
confirmed congenital abnormalities were excluded.   
After the child first birthday a health check was done. Children 
with diagnosis of genetic obesity or that underwent steroid therapy or 
assumed other appetite-enhancing drugs (anti-histamine and steroids) 
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for a prolonged period of time (at least 7 or more days) were ruled out 
(see Figure 10 for specific details of the study population).   
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Figure 11. Flow chart of the study population  
  
b. Clinical intervention and source of whole blueberry bioactive  
  
A freeze dried whole blueberry powder was prepared by the United 
States Highbush blueberry Council. The whole blueberry powder was 
made from a mixture of 50/50% of 2 varieties of highbush blueberries, 
Rubel (Vaccinium corymbosum) and Tifblue (Vaccinium ashei).   
The whole blueberries were freeze-dried, milled, and stored in 
aluminium cans under nitrogen. The 45 g of blueberry powder 
contained 1462 mg of total phenolics, 668 mg of anthocyanins, and 
16.02 mmol TE of antioxidants (oxygen radical absorbance capacity). 
Also, the 45 g of blueberry powder that was provided to the 
participants equated to an amount of bioactive in 2 cups of fresh 
whole blueberries.   
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All pregnant women of Phase 2 of the study (n = 105) agreed to 
receive twice daily a smoothie with blueberry bioactive added during 
the last trimester of pregnancy (starting from the 28th week of 
gestation).   
The participants were instructed to consume 1 smoothie at 
breakfast meals and the other smoothie at dinner meals (at least 6 h 
apart). The smoothies were prepared in the metabolic kitchen and a 
supply of frozen smoothies was provided in a cooler for the 
participants to pick up at each monthly visit.   
Participants were instructed to keep the smoothies frozen, thaw 
them in the refrigerator, avoid exposing them to direct heat, and avoid 
adding any other ingredients to them.   
For study compliance, the participants verbally reported their 
smoothie consumption to the dietitian at each visit. A compliance of 
>75% was mandatory for continued participation in the study.   
  
c. Food records and questionnaire  
  
At the screening visits a registered dietitian instructed 
participants to record a detailed food record. Participants were asked 
to provide labels and/or recipes for accuracy of the food records. The 
dietitian reviewed the food records for accuracy and completeness.   
Based on their eating patterns and usual intake, participants 
were counselled by the dietitian on ways to remove ≈2000 kj/d (500 
kcal/d) from their daily intake to compensate for the energy consumed 
in the blueberry and placebo smoothies.   
Participant were asked to maintain their current body weight 
and physical activity or they would be extruded from the study. The 
participants body weight were measured monthly to monitor weight 
maintenance. A change of ≥ 1 kg of body weight was addressed by the 
dietitian and proper counselling was provided. They also reported 
adverse events and changes in medication during the study.   
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Smoothie rating and fruit/wine questionnaires were also used in 
the study. Before starting the study, participants were given the 
opportunity to taste the smoothie for acceptability.   
The fruit/wine questionnaire was administered at each visit as a 
reminder to abstain from berries, grapes, juices that contained berries 
and grapes, and wine throughout the study. The rationale for these 
questionnaires was to eliminate consumption of 
anthocyanincontaining foods and drinks.   
  
d. Clinical evaluation  
  
All pregnant women underwent a complete auxological 
evaluation. Body mass index (BMI) was calculated by dividing weight 
(kg) by height squared (m2) and mothers were classified as normal (< 
25 kg/m2), overweight (≥ 25 kg/m2) according to the World Health 
Organisation criteria.   
The clinical evaluation of the new-born was conducted at day 1 
and included a general visit for detection of any sign of disease.  
Length and weight were measured using a Marsden M-400-80D 
Baby Scale with Height Rod. Head circumference was measured using 
a SECA measuring tape from the most prominent part of the forehead 
(often 1-2 fingers above the eyebrow) around to the widest part of the 
back of the head.   
A large for gestational age new-born was classified using the 
WHO Child growth standards based on length/height, weight and 
age27.   
The clinical evaluation of children at age one included height, 
weight and waist circumference.   
Height was determined using a Leicester portable height 
measure (SECA, Hamburg, Germany) and weight using a Marsden 
MS4102 weighing scale (Oxfordshire, United Kingdom). Waist 
circumference was measured midway between the coastal border and 
the iliac crest to the nearest millimetre using a SECA measuring tape.   
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Normal, overweight or obese children were classified using the  
WHO Child growth standards based on length/height, weight and age.   
A condition of overweight and obesity at age one was defined 
for BMI z-scores over 97th percentile and over 99th percentile on 
specific children BMI scale, respectively.   
  
e. Biochemical assays  
  
Blood samples were obtained from healthy pregnant women at 
36th week of gestation during a healthy regular gynaecological check; 
women with recent (one week) inflammatory disease were excluded 
from the study. Serum was separated and kept frozen at -70°C until 
analysis. The subsequent variables were studied:  
  
i. Proinflammatory adipocytokines  
  
Serum levels of cytokines TNF-α were measured using 
commercial available ELIZA kits (Ani Biotech Orgenium Laboratories 
Business Unit, Finland) Bender MedSystems GmbH Campus Vienna 
biocentre and the sensitivity of detection for TNF-α was 2.3 pg/mL; 
Leptin levels were measured  with an ELIZA procedure using 
commercial kits (Diagnostic Biochem Canada Inc. 1020 Hargrieve Road) 
and the sensitivity of detection level was 0.5 ng/mL. Serum levels of 
IFN-γ were analysed using ELISA method (R&D Systems, Wiesbaden, 
Germany) and the sensitivity of detection was 8 pg/mL.   
  
ii. Anti-inflammatory adipocytokines  
  
TGF-β was measured using ELISA method (R&D Systems, 
Wiesbaden, Germany) and the sensitivity of detection was 15.4 pg/mL. 
Serum IL-4 levels were determined with an enzyme-linked 
immunosorbent assay (ELIZA) technique using commercial kits 
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(Orgenium Laboratories, FIN-00790, Helsinki, Finland) and the 
sensitivity of detection was <7 pg/ml.   
   
iii. Indicator of systemic inflammation  
  
Serum samples were analysed for high sensitivity CRP level by 
turbidimetry (ADVIA 2400, Siemens Healthcare GmbH, Erlangen, 
Germany).  
  
f. Statistical analysis  
  
Analyses were performed using GraphPad Prism version 7. 
Differences between the blueberry and control group were analysed 
by a 2 sample t-test (continuous data) and within groups analysed by a 
paired t-test. P values  ≤ .05 were considered statistically significant. 
Data were expressed as means ± SEM.   
  
4. Results  
  
a. Study population  
  
i. Pregnant women  
  
112 women entered in the control group and 105 in the 
blueberry treated group. The two population were age-matched and 
did not differ in education. Furthermore the two groups did not differ 
in body weight or adiposity and in energy and macronutrient 
consumption (protein, carbohydrate, and fat; data not shown). In both 
groups the percentage of caesarean section (programmed and/or 
urgent) was similar (see Table 2).   
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ii. New-born  
  
Of all new-born, 98 patients entered in the control group and 92 
in the blueberry group. A slight prevalence of female was seen in the 
control group (53 vs 51%, respectively). 7% of the new-born in the 
control group were defined as large for gestational age (LGA). No LGA 
infant was detected in the blueberry group. Gestational age was similar 
(see Table 2).   
  
iii. Childhood  
  
At age one, 91 patients in the control group and 83 in the 
blueberry group were studied. Exclusive breastfeeding for 6 months 
was registered in similar percentage in the two groups. In the control 
group, 18% of the children were overweight and 7% were obese. In the 
blueberry group 13% of the children were overweight and 7% were 
obese (see Table 2).   
  
Variables  Control  Blueberry  
Pregnancy:      
Race (Caucasian/other), n/n  87/25  80/25  
Age, y  29 ± 3  30 ± 2  
Education:      
After primary school, n/n  62/112  58/105  
Overweight, n/n  73/112  77/105  
Obese, n/n  39/112  28/105  
Median BMI, kg/m2  28,98 ± 0,29  28,2 ± 0,28  
Median BMI in overweight, kg/m2  27,24 ± 0,2  26,71 ± 0,15  
Median BMI in obese, kg/m2  32,55 ± 0,27  32,3 ± 0,36  
Caesarean section, n/n  30/112  29/105  
      
Birth:      
Sex, m/f  46/52  45/47  
Gestational age, days  273 ± 8  275 ±5  
LGA, n/n  7/98  0/92  
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Offspring (age one):      
Sex, m/f  43/48  42/41  
Breastfeeding for 6 months, n/n  50/91  46/83  
Overweight, n/n  16/91  11/83  
Obese, n/n  6/91  6/83  
  
Table 2: anthropometrics and other variables of examined pregnant women, new-born and children in control 
group and in the blueberry treated group *.   
*Values are means ± SEM.  
  
  
b. Adipocytokines  
  
Blood samples was tested in 27 age and weight-matchedhealthy 
pregnant women in the control group and in 27 pregnant women in 
the blueberry group (after a treatment of 8 week with blueberry 
bioactive).   
Levels of pro-inflammatory cytokines (TNF-α; Leptin) and CRP 
were significantly lower in the blueberry group. Parallelly levels of 
antiinflammatory cytokines were significantly higher in the blueberry 
group. No difference was seen for levels of IFN-γ between the two 
groups (see Table 3 and Figure 11 for details).   
  
Variables  Control  Blueberry  Significance  
Cytokines:        
Pro-inflammatory        
TNF-α (pg/mL)  29,89 ± 0,283, n=27  8,124 ± 0,1085, n=27  P <.0001  
Leptin  (ng/mL)  17,28 ± 0,4742, n=27  6,977 ± 0,1187, n=27  P <.0001  
IFN-γ (pg/mL)  72,77 ± 1,522, n=27  70,46 ± 1,684, n=27  P = .31  
        
Anti-inflammatory        
IL-4 (pg/mL)  4,196 ± 0,9752, n=27  14,87 ± 0,8844, n=27  P <.0001  
TGF-β (pg/mL)  14,87 ± 0,8844, n=27  55,22 ± 1,47, n=27  P <.0001  
        
C-Reactive Protein 
(mg/L):   
5,917 ± 0,698, n=27  3,741 ± 0,6279, n=27  P = .024  
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Table 3: comparison between pro-inflammatory, anti-inflammatory cytokines and adipokines and C-reactive 
protein levels in overweight and obese pregnant women in control and in the blueberry group*.   
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c. Birth weight  
  
Birth weight improved significantly in the blueberry group. In 
particular male and female birth weight reduced significantly (male: 
3636 gr ± 56,7 in control group and 3302 gr ± 60,9 in the blueberry, 
P=.001; female: 3446 gr ± 53 in control group and 3094 gr ± 65,5 in the 
blueberry, P<.0001), see Figure 13 for details.   
  
d. Weight at age one  
  
At one year of age weight continues to remain significantly lower 
in the blueberry group. Precisely male weight reduced significantly in 
the blueberry group (control: 9597 gr ± 134,4; blueberry: 8656 gr ± 
271,9; P=.0021) and the same happened in females (control: 8812 ± 
167,5; blueberry: 8083 ± 266,3; P=.0211); see Figure 13 for details.  
     
  
  
C   
Figure  12 : 
  Comparison between pro -   and anti - inflammatory cytokines levels in overweight and obese  
pregnant women in control and in the blueberry group.  A . Mean change in IFN - γ ; TNF - α 
  and Leptin levels  
between control a nd 
  blueberry group. A significative  lower level   of inflammatory cytokines was seen in the  
blueberry group according to TNF - α 
  and Leptin; no difference was seen for levels of IFN - γ . B.   Mean change in  
TGF - β 
  and IL - 4 levels between control and blueberry group. A significative   higher level   of anti - inflammat ory  
cytokines was seen after treatment with blueberry.  C   Levels of C : - reactive proteins, marker of systemic  
inflammation, in control and blueberry group. Notice the significative  lower 
  CRP levels in the blueberry group.  




Figure 13: Mean change in birth weight and weight at age one in male and female whose mothers  consumed 
or not the blueberry smoothie. Values are means ± SEM, male: n=46 (control) or 45  
(blueberry) at birth and n=48 (control) or 45 (blueberry) at age one; female: n=52 (control) or 47  (blueberry) at 
birth and n=48 (control) or 45 (blueberry) at age one.  
  
5. Discussion  
  
To our knowledge this is the first controlled clinical trial that 
evaluates the effect of a daily blueberry consumption in overweight 
pregnant women and specifically on their cytokine milieu.   
The two population studied, although tested in different period, 
were identical in physical appearance and macronutrient content with 
the exception of adding the blueberry bioactive to the blueberry 
smoothies.   
Our dietitian worked with the participants during the monthly visits 
to eliminate its calories from their diets to compensate for the energy 
provided by the smoothies and the constant supervision of our medical 
doctor and dietitian helped our population in maintaining a stable 
body weight and physical activity throughout the whole study without 
making them potential confounding factors.   
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Breastfeeding period and time of weaning were similar in the two 
population ruling them out as other potential confounders.   
Consumption of smoothies has been demonstrated to be an 
attractive and convenient dietary approach for those adults who do 
not consume the recommended daily amounts of fruits and 
vegetables. Our study population appreciated this form of integration: 
the compliance reached 92% (data not shown).   
Persistent data’s have clearly linked inflammation to adiposity with 
significant report on the mechanisms by which inflammation at whole 
body level attenuates insulin action28 that is consequently secreted in 
higher quantities.   
Overweight women tends to have hyperglycaemia that associated 
with higher levels of inflammation leads to foetal hyperinsulinemia,  
increased utilization of glucose and, hence, increased foetal adipose 
tissue and foetal macrosomia (modified Pedersen’s Hypothesis, see 
Figure 14 for details)29.  
  
  
Figure 14: Results of maternal hyperglycaemia modified according to Pedersen’s hypothesis  
  
Blueberry bio-active compounds have been demonstrated to 
endow antioxidant properties (radical scavenging)30 and to improve 
insulin sensitivity in obese, non-diabetic and insulin resistant 
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individuals26. Vuong T et al. found that 6-hours treatment of fermented 
blueberry juice with and without insulin increased glucose uptake into 
the muscle and adipocyte cells31.   
Contrary to what was seen by Stull J et al, and according to 
DeFuria et al, in our case a consumption of daily doses of bioactive in 
blueberries, is capable in altering the inflammatory biomarker profile 
and in particular it significantly reduces levels of TNF-α, a 
proinflammatory cytokine that exerts numerous effects in adipose 
tissue and that reduces anti-inflammatory cytokines like adiponectin 
and of Leptin, an inflammatory adipokine secreted primarily by fat cells 
ant that acts centrally particularly in the hypothalamus, is reduced.   
Curiously and parallelly we discovered that IL-4, a cytokine that 
inhibits lipid accumulation in fat tissues, is significantly elevated in the 
blueberry group as well as TGF-β, a well-known cytokine with 
immunosuppressive and healing properties32, that is significative 
increased after blueberry consumption.   
Therefore one of the major findings of our study is that 
blueberry bioactive are capable to reduce the inflammatory status by 
inducing a switch to a more tolerogenic cytokine milieu. As a result 
insulin sensitivity is increased, levels of insulin are reduced and protein 
and fat stores are consequently reduced in the foetus (see Figure 15).  
 The final confirmation of these properties is demonstrated by the 
significative reduction of a systemic marker of inflammation such as 
the CRP.   
Another major finding of our study was that a daily integration of 
whole blueberry bioactive reduced significantly birth weight (parallelly 
the risk of delivering an LGA infant) and consequently the risk of 
serious adverse pregnancy outcome. More interestingly this result is 
maintained in the offspring because weight at age one was still 
significantly reduced in mothers who consumed blueberry extracts.   
Our study gives us a possible confirmation that epigenetic has a 
dynamic nature and that nutrients and their metabolites can be direct 
activators or inhibitors of the epigenetic machinery enzymes33.   
The persistence of this beneficial effect on children at age one 
could be a direct effect of an altered epigenetic machinery enzymes or 
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a direct effect on the foetus metabolic ambient; in fact flavonoids are 
able to pass the placenta34 and therefore able to exert their antioxidant 
properties directly on the foetus.   
Further studies are needed in this field in order to better 
understand this interesting result.   
  
  
Figure 15: Beneficial effects of blueberry consumption in overweight pregnant women; Its bioactive 
compounds are able to reduce inflammation by inducing tolerogenic cytokines and consequently reduce insulin 
release an ameliorate glucose utilization with the final effect of a reduced fat and protein deposition in the 
foetus and therefore reduced birth weight and weight at age one.  
  
6. Conclusion  
  
In conclusion we can affirm that a 12 week daily supplementation 
of bioactive in freeze-dried whole blueberry powder in the last 
trimester of pregnancy of overweight pregnant women, in association 
with a regular dietary surveillance, is able to reduce the inflammatory 
cytokine milieu hence inducing a better insulin sensitivity with the final 
result of reducing birth weight and at age one.  
Considering its feasibility this could be an efficacious way to 
prevent childhood obesity.  
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